Evidence map›Paper›PMID 35745832›Full record

ArticlePharmaceutics2022

VEGF Overexpression Significantly Increases Nanoparticle-Mediated siRNA Delivery and Target-Gene Downregulation.

Shanshan Tan, Zhihang Chen, Yelena Mironchik, Noriko Mori, Marie-France Penet, Ge Si, Balaji Krishnamachary, Zaver M Bhujwalla

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Shanshan TanDivision of Cancer Imaging Research, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD 21205, USA.ORCID 0000-0002-4303-3916
Zhihang ChenDivision of Cancer Imaging Research, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD 21205, USA.ORCID 0000-0003-1553-3312
Yelena MironchikDivision of Cancer Imaging Research, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD 21205, USA.
Noriko MoriDivision of Cancer Imaging Research, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD 21205, USA.
Marie-France PenetDivision of Cancer Imaging Research, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD 21205, USA.
Ge SiDivision of Cancer Imaging Research, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD 21205, USA.ORCID 0000-0003-1554-6551
Balaji KrishnamacharyDivision of Cancer Imaging Research, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD 21205, USA.
Zaver M BhujwallaDivision of Cancer Imaging Research, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD 21205, USA.
Morgan State University · USJohns Hopkins University · USSidney Kimmel Comprehensive Cancer Center · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Training/Dissemination-Resource for Molecular Imaging Agents in Precision MedicineP41EB024495 · NIBIB · UT SOUTHWESTERN MEDICAL CENTER · PI MARTIN G POMPER · 2017 to 2026
$11.8M
Molecular Imaging and Theranostics of CancerR35CA209960 · NCI · JOHNS HOPKINS UNIVERSITY · PI BHUJWALLA, ZAVER M. · 2017 to 2023
$6.5M
HOSTILE ENVIRONMENTS PROMOTE INVASION AND METATASISR01CA082337 · NCI · JOHNS HOPKINS UNIVERSITY · PI BHUJWALLA, ZAVER M. · 1999 to 2024
$5.1M
The Tumor Microenvironment in Nanoparticle Delivery and FunctionR01CA253617 · NCI · JOHNS HOPKINS UNIVERSITY · PI BHUJWALLA, ZAVER M. · 2020 to 2024
$1.8M
INTEGRATING MOLECULAR BIOLOGY WITH CANCER MOLECULAR IMAGING AND THERANOSTICSR50CA243562 · NCI · JOHNS HOPKINS UNIVERSITY · PI KRISHNAMACHARY, BALAJI · 2021 to 2025
$467k
NCI NIH HHS P30 CA006973NCI NIH HHS R01 CA082337NCI NIH HHS R01 CA253617NCI NIH HHS R35 CA209960NCI NIH HHS R50 CA243562NIBIB NIH HHS P41 EB024495
6 · The paper itself

Abstract

The availability of nanoparticles (NPs) to deliver small interfering RNA (siRNA) has significantly expanded the specificity and range of 'druggable' targets for precision medicine in cancer. This is especially important for cancers such as triple negative breast cancer (TNBC) for which there are no targeted treatments. Our purpose here was to understand the role of tumor vasculature and vascular endothelial growth factor (VEGF) overexpression in a TNBC xenograft in improving the delivery and function of siRNA NPs using in vivo as well as ex vivo imaging. We used triple negative MDA-MB-231 human breast cancer xenografts derived from cells engineered to overexpress VEGF to understand the role of VEGF and vascularization in NP delivery and function. We used polyethylene glycol (PEG) conjugated polyethylenimine (PEI) NPs to deliver siRNA that downregulates choline kinase alpha (Chkα), an enzyme that is associated with malignant transformation and tumor progression. Because Chkα converts choline to phosphocholine, effective delivery of Chkα siRNA NPs resulted in functional changes of a significant decrease in phosphocholine and total choline that was detected with

Indexed as

choline kinasenanoparticlessiRNA deliverytriple negative breast cancervascularization

Identifiers

PMID35745832
PMCPMC9229257
OpenAlexW4282973870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.